Beatrijs Wokke
Overview
Explore the profile of Beatrijs Wokke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blok K, Klein Kranenbarg R, Ananth K, Engelenburg H, van den Bosch A, Giannini L, et al.
Eur J Neurol
. 2025 Feb;
32(2):e70052.
PMID: 39907163
Background: Relapsing-remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory...
2.
Smets I, Versteegh M, Huygens S, Wokke B, Smolders J
Mult Scler
. 2024 Jun;
30(8):1016-1025.
PMID: 38859625
Background: Uncertainty about disproportionate impact on health care budgets limits implementation of early highly effective treatment (EHT) in multiple sclerosis (MS). Objective: To estimate cost-effectiveness of escalation versus EHT disease-modifying...
3.
van Puijfelik F, Blok K, Klein Kranenbarg R, Rip J, de Beukelaar J, Wierenga-Wolf A, et al.
Brain Commun
. 2024 Feb;
6(1):fcae021.
PMID: 38385000
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however, subpopulations of CD4 and CD8 T cells in peripheral blood...
4.
Willekens B, Kleffner I, Wokke B
Front Neurol
. 2023 Dec;
14:1342817.
PMID: 38152643
No abstract available.
5.
Blok K, van Rosmalen J, Tebayna N, Smolders J, Wokke B, de Beukelaar J
Front Neurol
. 2023 Nov;
14:1277477.
PMID: 38020591
Background: Disease activity in multiple sclerosis (MS) is defined as presence of relapses, gadolinium enhancing lesions and/or new or enlarging lesions on MRI. It is associated with efficacy of immunomodulating...
6.
Blok K, Smolders J, van Rosmalen J, Martins Jarnalo C, Wokke B, de Beukelaar J
Eur J Neurol
. 2023 Aug;
30(12):3799-3808.
PMID: 37578087
Background And Purpose: Despite the 2017 revisions to the McDonald criteria, diagnosing primary progressive multiple sclerosis (PPMS) remains challenging. To improve clinical practice, the aim was to identify frequent diagnostic...
7.
Smets I, Versteegh M, Huygens S, Corsten C, Wokke B, Smolders J
Mult Scler J Exp Transl Clin
. 2023 Aug;
9(3):20552173231189398.
PMID: 37529628
Background: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices...
8.
Smets I, Wokke B, Smolders J
Mult Scler
. 2022 Jul;
29(2):308-310.
PMID: 35822293
No abstract available.
9.
Koetzier S, van Langelaar J, Melief M, Wierenga-Wolf A, Corsten C, Blok K, et al.
Cells
. 2022 May;
11(10).
PMID: 35626671
The effector programs of CD8 memory T cells are influenced by the transcription factors RUNX3, EOMES and T-bet. How these factors define brain-homing CD8 memory T cells in multiple sclerosis...
10.
Nowak V, Bremner F, Massey L, Wokke B, Moosavi R, Kara E, et al.
Pract Neurol
. 2014 Jun;
14(4):278-9.
PMID: 24924740
No abstract available.